1.
Urol Nurs
; 32(1): 38-46, 50, 2012.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22474864
RESUMO
In this post-hoc analysis of data from patients with overactive bladder (OAB) in VIBRANT patients receiving solifenacin showed statistically significantly greater improvement versus placebo in most outcome measures regardless of OAB symptom duration (less than five years and five years or longer).